摘要
目的分析吉非替尼(gefitinib)联合化学治疗方案应用于晚期肺腺癌患者所产生的临床疗效及安全性。方法选取2016年10月至2018年6月在我院收治的80例晚期肺腺癌,以随机数字表作为分组工具,分为研究组38例和对照组42例,研究组给予吉非替尼联合化疗方案治疗,对照组给予厄洛替尼联合化疗方案治疗。比较两组患者的临床疗效、肿瘤大小变化情况和不良反应发生情况。结果研究组总控制率为73.7%,高于对照组的50.0%,差异有统计学意义(P<0.05);研究组肿瘤增大所占比例为13.2%,低于对照组的35.0%,差异有统计学意义(P<0.05);研究组骨髓抑制、肝损害的发生率分别为47.4%、31.6%,低于对照组的74.0%、65.0%,差异有统计学意义(P<0.05)。结论吉非替尼应用于晚期肺腺癌患者,能协同提高抗癌效果,且能减少躯体不适反应的发生率,亦能控制癌细胞增殖,可考虑将其作为抗癌方案之一。
Objective To analyze the clinical efficacy and safety of gefitinib combined with chemotherapy in the treatment of advanced lung adenocarcinoma.Methods Eighty patients with advanced lung adenocarcinoma admitted to our hospital from October 2016 to June 2018 were selected for this study.The patients were divided randomly into a study group(n=38)and a control group(n=42).The study group received treatment regimen of gefitinib combined with chemotherapy,while the control group received treatment regimen of erlotinib combined with chemotherapy.The clinical efficacy,tumor size changes and incidence of adverse reactions were compared between the two groups.Results The total control rate of the study group was 73.7%,higher than that of the control group(50.0%),with statistical significant difference between the two groups(P<0.05).The proportion of tumor enlargement in the study group was 13.2%,lower than that of the control group(35.0%),with statistical significant difference between the two groups(P<0.05).The incidences of bone marrow depression and liver damage in the study group were 47.4%and 31.6%,respectively,which were lower than those of the control group(74.0%and 65.0%,respectively),with statistical significant difference between the two groups(P<0.05).Conclusion Gefitinib can improve the anticancer effect of advanced lung adenocarcinoma,reduce the occurrence of somatic discomfort,and control the proliferation of cancer cells.Therefore,gefitinib may be considered as an anticancer regimen.
作者
曹参
李靖
吴勤研
Cao Shen;Li Jing;Wu Qinyan(Pharmaceutical Department, General Hospital of Eastern Theater Command, Nanjing 210000, China)
出处
《中华肺部疾病杂志（电子版）》
CAS
2020年第4期484-487,共4页
Chinese Journal of Lung Diseases(Electronic Edition)
基金
江苏省药学会科研立项(A201707)。
关键词
肺腺癌
吉非替尼
联合化疗
临床疗效
安全性
Lung adenocarcinoma
Gefitinib
Combined chemotherapy
Clinical efficacy
Safety
作者简介
通信作者:李靖,Email:773913218@qq.com。
